BACKGROUND The coronavirus disease 2019(COVID-19)has been the cause of a global health crisis since the end of 2019.All countries are following the guidelines and recommendations released by the World Health Organizat...BACKGROUND The coronavirus disease 2019(COVID-19)has been the cause of a global health crisis since the end of 2019.All countries are following the guidelines and recommendations released by the World Health Organization to decrease the spread of the disease.Children account for only 3%-5%of COVID-19 cases.Few data are available regarding the clinical course,disease severity,and mode of treatment in children with malignancy and COVID-19.AIM To evaluate the treatment plan and outcome of children with malignancy who contracted COVID-19.METHODS A retrospective study of the medical files of patients with malignancy who contracted COVID-19 between July 2020 and June 2021 was performed.The following data were reviewed for all patients:primary disease,laboratory data,admission ward,clinical status upon admission,disease course,treatment plan,and outcome.Eligible patients were those with malignancy who tested positive for COVID-19 by reverse transcription polymerase chain reaction.RESULTS A total of 40 patients who had malignancy contracted COVID-19 from July 1,2020 to June 1,2021.Their primary diseases were as follows:34 patients(85%)had hematological malignancies(30 had acute lymphoblastic leukemia,2 had acute myeloblastic leukemia,and 2 had Hodgkin lymphoma),whereas 6 patients(15%)had solid tumors(2 had neuroblastoma,2 had rhabdomyosarcoma,and 2 had central nervous system tumors).Twelve patients(30%)did not need hospitalization and underwent home isolation only,whereas twenty-eight patients(70%)required hospitalization(26 patients were admitted in the COVID-19 ward and 2 were admitted in the pediatric intensive care unit).CONCLUSION COVID-19 with malignancy in the pediatric age group has a benign course and does not increase the risk of having severe infection compared to other children.展开更多
文摘BACKGROUND The coronavirus disease 2019(COVID-19)has been the cause of a global health crisis since the end of 2019.All countries are following the guidelines and recommendations released by the World Health Organization to decrease the spread of the disease.Children account for only 3%-5%of COVID-19 cases.Few data are available regarding the clinical course,disease severity,and mode of treatment in children with malignancy and COVID-19.AIM To evaluate the treatment plan and outcome of children with malignancy who contracted COVID-19.METHODS A retrospective study of the medical files of patients with malignancy who contracted COVID-19 between July 2020 and June 2021 was performed.The following data were reviewed for all patients:primary disease,laboratory data,admission ward,clinical status upon admission,disease course,treatment plan,and outcome.Eligible patients were those with malignancy who tested positive for COVID-19 by reverse transcription polymerase chain reaction.RESULTS A total of 40 patients who had malignancy contracted COVID-19 from July 1,2020 to June 1,2021.Their primary diseases were as follows:34 patients(85%)had hematological malignancies(30 had acute lymphoblastic leukemia,2 had acute myeloblastic leukemia,and 2 had Hodgkin lymphoma),whereas 6 patients(15%)had solid tumors(2 had neuroblastoma,2 had rhabdomyosarcoma,and 2 had central nervous system tumors).Twelve patients(30%)did not need hospitalization and underwent home isolation only,whereas twenty-eight patients(70%)required hospitalization(26 patients were admitted in the COVID-19 ward and 2 were admitted in the pediatric intensive care unit).CONCLUSION COVID-19 with malignancy in the pediatric age group has a benign course and does not increase the risk of having severe infection compared to other children.
